What are the key regional markets in the global dehydrated Biopharmaceutical Excipients market industry?

The global biopharmaceutical excipients market size is expected to reach USD 3.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028. The factors driving the market growth include increasing development of biosimilars, instability associated with drugs & vaccines, and growing focus on the development of novel drugs, among others.

The changing regulatory scenarios by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have impacted drug development. Several legislative proposals are addressing new ways for lowering the cost of prescription drugs. Similarly, in recent years there is an increasing focus on drug-manufacturing quality has led to several recalls by FDA and the EMA. Hence, the stringent investigations related to an examination of drugs are likely to promote the use of specific excipients for developing efficient drugs.

In addition, companies are collaborating with government authorities for increasing the application of novel compounds. For instance, in December 2019, U.S. FDA started a pilot program to evaluate novel biopharmaceutical excipients. Later, the initiative was supported by several companies such as AstraZeneca, Regeneron, and Janssen for FDA’s plan to review novel biopharmaceutical excipients. Regeneron highlighted different novel compounds that can potentially help in improving public health for example hydrophobic salts can reduce the viscosity of highly concentrated antibody formulations.

Biopharmaceutical Excipients Market Segmentation

Grand View Research has segmented the global biopharmaceutical excipients market on the basis of product and region:

Based on the Product Insights, the market is segmented into Solubilizers & Surfactants/Emulsifiers, Polyols, Carbohydrates and Specialty Excipients.

• Carbohydrate-based excipient products dominated the market in 2020, with a share of 36.2%, and this trend is expected to continue through the forecast period. The extensive use of starch, sucrose, and dextrose in various drug formulations can be primarily attributed to the dominant share of the segment.
• The starch segment is expected to witness the fastest CAGR of 6.6% owing to its wide application in drug development. It can act as an efficient binder, diluent, and disintegrant that can be used for various non-prescription medications, biopharmaceuticals, and food supplements.
• The polyols segment is expected to witness a lucrative growth rate of 6.7% from 2021 to 2028. The growth in the segment can be attributed to the increasing protein therapeutics. Polyols are added in protein formulations for increasing tonicity and stability. Moreover, it has also been shown to offer greater thermodynamic stability which is highly essential for protein-based formulations.

Biopharmaceutical Excipients Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Key Companies Profile & Market Share Insights

Companies are launching new and advanced excipient solutions for supporting pharmaceutical drug development. For instance, in April 2020, DFE Pharma launched a new portfolio of biopharmaceutical excipients for stabilizing biologics. BioHale, the new range of excipient portfolio, consists of the highest purity excipients that can be used in the formulation. It contains BioHale Sucrose and BioHale Trehalose that is currently under development and will be available through online sales.

Some prominent players in the Global Biopharmaceutical Excipients market include:

• Merck KGaA
• Signet Excipients Pvt. Ltd
• Sigachi Industries Limited
• Associated British Foods plc
• Spectrum Chemical Manufacturing Corp.
• Roquette Frères
• IMCD
• Clariant
• DFE Pharma
• Colorcon
• BASF SE
• Evonik Industries AG
• J. RETTENMAIER & SÖHNE GmbH + Co KG

Order a free sample PDF of the in Biopharmaceutical Excipients Market Intelligence Study, published by Grand View Research.